|Articles|September 23, 2022
Antibody-based drug discovery at the speed of light
Author(s)Curia
The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
VectorY Doses First Patient in TDP-43–Targeting ALS Trial
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
Ivonescimab Breakthrough Designation Highlights Progress in BTC Treatment
5